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Whether chronic inflammation mirrored by high levels of systemic inflammatory markers such as high sensitive-CRP (hs-CRP)
and white blood cell count (WBC) are associated with prostate cancer development remains unclear. In the Prostate Cancer
Study throughout Life (PROCA-life), a prospective population-based cohort study, 7,356 men were included. Prediagnostic WBC
and hs-CRP were assessed from blood collected at study entry; 2,210 participants also had a second CRP measure during
follow-up. During a mean 11.8 years follow-up, 509 men developed prostate cancer (mean age at diagnosis 71.7 years).
Multivariable Cox proportional hazard regression models were used to study whether individual biomarkers (WBC, hs-CRP), a
combined score based on analyte tertiles (score range 2–6), or change in CRP were associated with risk and severity of
prostate cancer. We observed a positive dose–response relationship between hs-CRP and prostate cancer risk with a Hazard
Ratio (HR) per mg/l of 1.3, 95% CI 1.00–1.07. Men with an increase in hs-CRP between two measurements (Δhs-CRP) of
≥1.00 mg/l had a 36% increased risk of prostate cancer (HR 1.36, 95% CI 1.02–1.82), compared to men with no change or
decrease in hs-CRP. Men with a systemic inflammatory score of 5 or 6 had a 68% higher risk of being diagnosed with
metastatic disease (HR 1.68, 95% CI, 1.04–2.73) compared to men with lower scores. Our study supports that hs-CRP including
repeated measurements alone or in combination with WBC may be a useful inflammation-related biomarker for prostate cancer
risk and prognosis.
Additional Supporting Information may be found in the online version of this article.
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Introduction
Chronic inflammation, one hallmark of cancer development1
has been questioned as playing a key role in prostate cancer
development. The suggested hypothesis is partly based on
observations of inflammatory cells in the prostate microenvi-
ronment of adult men, and on inflammation being associated
with precursor lesions in the prostate gland, termed prolifera-
tive inflammatory atrophy. However, a causal relationship
between inflammation and prostate cancer development—one
of the most common invasive cancers among men globally—
has yet to be established.2–4
Currently, prostate-specific antigen (PSA) is the only non-
invasive biomarker in clinical use to detect and evaluate effi-
cacy of prostate cancer treatment, but has a low sensitivity in
prostate cancer diagnosis.5 However, PSA testing has led to a
dramatic increase in incidence of prostate cancer, and the
majority of prostate cancer cases have been localized disease.6
Key challenges in diagnostics of prostate cancer are to develop
better tools to identify individuals at high risk for prostate
cancer, and to distinguish between tumors with a low malig-
nant potential that are unlikely to require therapeutic inter-
vention compared to tumors that should be treated.
Blood levels of two commonly available measures—C-reactive
protein (CRP) and white blood cell count (WBC) are indicators
of systemic inflammation. Interesting observations suggest that
these biomarkers could predict risk for prostate cancer develop-
ment and progression.7–10 CRP is an acute phase protein that
reflects tissue injury and has become a widely used systemic bio-
marker of acute infection or inflammation in clinical practice.
CRP is relatively stable in serial measurements in healthy indi-
viduals.11,12 Furthermore, local inflammation has been observed
in 35–100% of prostate cancer biopsies.2,13–15
Previous studies investigating the association between CRP
and risk for prostate cancer development have shown conflicting
results, as some studies found positive associations between level
of inflammation-related biomarkers and risk of prostate can-
cer7,16,17; others have not.16–24 However, most studies have
included only one single measurement of CRP, with a limited
number of prostate cancer cases and short follow-up time.7,16–24
The aim of the present study was to investigate associa-
tions between the inflammation-related biomarkers CRP and
WBC and risk of prostate cancer development and severity.
A second aim is to determine whether markers of inflamma-
tion (WBC and high sensitivity-CRP, hs-CRP) independently
or in combination were associated with risk and severity of pros-
tate cancer, and to look at change in CRP and risk of prostate
cancer development and severity. The Prostate Cancer Study
throughout life (PROCA-life) study includes a subset of men
included in the population-based Tromsø Study, who had avail-
able measures of CRP and WBC.
Methods
Study population
The PROCA-life study includes all men, age > 25 years who
enrolled in the population-based, prospective cohort Tromsø
study between 1994 and 2008 (Tromsø 4, 1994–1995, Tromsø
5, 2001, Tromsø 6, 2007–2008).25,26 The procedures were almost
identical and assessments were done by trained research techni-
cians. All age-eligible men in the Tromsø geographic area were
invited to participate via a personal written invitation, and non-
respondents were given one reminder. Once enrolled, all partici-
pants were invited to participate in the regular next follow-up
survey (second measurement). The attendance rate for men was
on average 67% in the three health surveys.26 For the present
study, only men who attended the second visit in Tromsø 4 or
Tromsø 5, and all men in Tromsø 6, were eligible (n = 7,720).
Measurements of prediagnostic hs-CRP > 20 mg/l and/or
prediagnostic WBC > 15 x 109cells/l, which may mirror other
acute or chronic diseases, were excluded (high hs-CRP: n = 285,
high WBC: n = 44). Participants with prevalent or previous can-
cer (n = 334), or who developed cancer within the first year after
the enrollment in the study (n = 58) were excluded to account
for the possibility that undiagnosed cancer or severe illness could
influence the results (Fig. 1). All men completed questionnaires,
blood draws and basic clinical measurements. The PROCA-life
study has been approved by the Regional Committee for Medical
and Health Research Ethics North (REK) (2015/1059). All partic-
ipants have signed consent declarations when enrolled in the
Tromsø Study.
Questionnaires and clinical assessments
Information about medical history, lifestyle factors, dietary fac-
tors, medication, smoking history, and level of physical activity
were obtained from the questionnaires. We defined being physi-
cal active as: more than 1 hour/week of strenuous exercise, or
any leisure time exercise more than two to three times/week.
Height and weight were measured on an electronic scale with
the participants wearing light clothing and no shoes. Height was
What’s new?
Although chronic inflammation likely influences prostate cancer development, a clear association is yet to be established. In
particular, uncertainties remain regarding the relationship between systemic inflammatory markers and prostate cancer. In this
investigation of data for more than 7,350 men, pre-diagnostic levels of C-reactive protein (CRP), measured via high-sensitivity
CRP (hs-CRP) testing at study entry and at follow-up, were associated with a dose-response increase in prostate cancer risk.
Risk and disease severity were further associated with a combined score incorporating both hs-CRP and white blood cell count,
highlighting the relevance of inflammation in prostate cancer development and prognosis.
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measured to the nearest centimeter (cm) and weight to the
nearest kilogram. BMI was calculated using the formula weight/
height2 (kg/m2).25 Blood pressure was measured three times in a
resting position, and the mean of the two last measurements
were used.
Assessment of serum inflammation-related biomarkers and
other serum markers
Blood samples were drawn by trained research assistants on
attendance at each survey, and were nonfasting. Analyses of
serum samples were done at the Department of Laboratory
Medicine, University Hospital of Northern Norway (UNN),
Tromsø, Norway.25 Serum samples from men who attended
the first two surveys (Tromsø 4 or 5: 1994–95 and/or 2001)
were kept frozen up to 12 years at −70C and later analyzed,
while hs-CRP was assessed in fresh samples from men who
attended the final survey (Tromsø 6: 2007–08). Hs-CRP was
analyzed by a particle-enhanced immune turbid metric assay
on a Modular P auto-analyzer (Roche Diagnostics, Mann-
heim, Germany) with reagents from the manufacturer with a
detection limit of 0.12 mg/l. For WBC counts, 5 ml of blood
was collected into Vacutainer tubes containing EDTA as an
anticoagulant (K3-EDTA 40 ll, 0.37 mol/l per tube), and ana-
lyzed within 12 hr by an automated blood cell counter
(Coulter CounterÒ, Coulter Electronics, Luton, UK and
Coulter LH750, Nerliens Meszansky). Total cholesterol was
analyzed by enzymatic colorimetric methods with commer-
cially available kits (CHOD-PAP for cholesterol). PSA mea-
surements were done for cancer cases only, as part of clinical
routine in diagnosis and follow-up (1990–1994 Stratus® PSA
Fluorometric Enzyme Immunoassay, 1994–2001 AxSYM Psa
Reagent Pack, Abbot®, 2001 Bayer® PSA Reagens Pack Immuno
I (Prod. Nr.T01-3450-51), Technicon Immuno I). For prostate
cancer cases diagnosed or treated in other institutions (n = 21),
PSA values from their local laboratories were recorded.
Identification of prostate cancer cases during follow-up
Prostate cancer cases during follow-up (until December 31,
2016) were identified by using the unique national 11-digit
identification number through linkage with the Cancer Regis-
try of Norway. Among 7,270 men that were included in our
study, 509 men were diagnosed with verified invasive prostate
cancer during follow-up, and there was no ongoing screening
programs for prostate cancer in Tromsø during the study
period. Follow-up time was calculated from date of entry into
the study, to the date of censoring (prostate cancer diagnosis,
emigration, death, or end of follow-up [December 31, 2016]).
Detailed clinical information for the prostate cancer cases
was obtained from the medical records (e.g., disease stage,
treatments, recurrence) by trained physicians (TK and ES).
All histopathological specimens were reexamined by the same
uropathologist (ER) and classified according to the latest
International Society of Urological Pathology (ISUP) guide-
lines on Gleason score and ISUP grade group.27
Prostate cancer cases were divided into four risk groups
based on PSA level at diagnosis, highest ISUP grade group
and clinical T-stage, according to the EAU guidelines.28 Risk
group 1 (low) was defined as: PSA < 10 μg/l, clinical T-stage
(cT-) 1, and ISUP grade group 1. Risk group 2 (intermediate)
was defined as: PSA: 10–20 μg/l, cT-stage 2, or ISUP grade
Figure 1. Flow chart for the population included in the PROCA-life study between 1994 and 2008.
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group 2–3. Risk group 3 (high) was defined as: PSA:
> 20–100 μg/l, cT-stage 3, or ISUP grade group 4–5. Risk
group 4 (metastatic) was defined as: PSA > 100 μg/l, or with
radiological evidence of metastatic disease. ISUP grade group
were reported after reclassification when available. PSA values
above 100 were not included in calculation of mean or
median PSA.
Statistical methods
Descriptive characteristics of the study population were pres-
ented as means (standard deviation) or percent (numbers). Dif-
ferences in the distribution of characteristics at study entry
between nonprostate cancer cases and prostate cancer cases were
assessed using t-tests for continuous variables and Chi-square
tests for categorical data. No large differences was observed
Table 1. Distribution of selected characteristics for men with prostate cancer (cases) and without prostate cancer (noncases) in the PROCA-life
Study (1994–2008)
Characteristics Overall (n = 7,270) Noncases (n = 6,761) Prostate cancer cases (n = 509)
Age at first attendance (years) 56.9 (10.5) 56.5 (10.6) 66.8 (7.6.)
Observation time (years) 11.8 (6.0) 11.9 (6.0) 9.9 (5.9)
Observation time ≤5 years (%) 5.8 4.3 24.8
Observation time 5.1–10 years (%) 59.9 61.9 33.2
Observation time > 10 years (%) 34.3 33.8 42.0
Systolic blood pressure (mm Hg) 137.7 (19.8) 137.2 (19.6) 143.3 (20.5)
Body mass index (kg/m2) 26.8 (3.67) 26.8 (3.7) 26.6 (3.6)
Serum samples at study entry
Total cholesterol (mmol/l) 5.98 (1.21) 5.96 (1.21) 6.19 (1.24)
Hs-CRP (mg/l) 2.10 (2.46) 2.10 (2.46) 2.17 (2.47)
Hs-CRP (mg/l) median (interquartile range) 1.28 (0.70–2.45) 1.27 (0.69–2.44) 1.36 (0.78–2.61)
White blood cells (x109/l) 6.62 (1.79) 6.61 (1.80) 6.75 (1.68)
White blood cells (x109/l) median (interqu. range) 6.3 (5.3–7.6) 6.3 (5.3–7.6) 6.4 (5.6–7.7)
Lifestyle factors at study entry
Lipid-lowering drugs, current use (%) 8.5 8.5 8.3
Current smokers (%) 26.7 26.6 28.5
Physically active (%) 41.0 41.1 39.2
Characteristics among prostate cancer cases
Age at diagnosis (years) 71.7 (7.5)
Cancer specific mortality (%) 8.8
PSA at diagnosis (μg/l)1 14.3 (14.3)
PSA at diagnosis, median (μg/l)1 9.9
Time from last blood sample to diagnosis (years) 5.4 (3.2)
Tumor characteristics
T-stage
T1 + T2 (%) 74.1
T3 + T4 (%) 22.0
Tx (%) 3.9
ISUP grade group
1–3 (Gleason score 6–7) (%) 72.7
4–5 (Gleason score 8–10) (%) 18.3







Numbers may vary due to missing information. Values are mean (standard deviation) unless otherwise specified.
Abbreviations: Hs-CRP, high sensitivity C-reactive protein; ISUP, International Society of Urological Pathology; PSA, prostate-specific antigen.
1PSA values above 100 are excluded from calculation of mean and median.
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between cases and noncases and therefore not shown in text or
tables. Multivariable Cox proportional hazard models were used
to investigate whether inflammation biomarkers (hs-CRP and
WBC) or repeated assessments of hs-CRP (Fig. 1) were associ-
ated with prostate cancer risk and severity, presented with hazard
ratio (HR) and 95% confidence interval (CI). The inflammatory
markers (hs-CRP and WBC) were not normally distributed, and
log-transformation was tested, but did not influence results.
To study the importance of the variation in inflammation-
related biomarkers in more detail, we used hs-CRP and WBC
both as continuous and categorical variables, with tertile cut-
points based on the distribution in the overall data set. Continu-
ous variables are presented as HR per unit increase. We defined
the systemic inflammatory score as the sum of tertile ranking for
hs-CRP and WBC: tertile 1. hs-CRP: ≥0.01 – ≤0.91 mg/l, WBC:
≥1.1 – ≤5.6 × 109/l/l, tertile 2. hs-CRP: ≥0.92 – ≤2.03 mg/l, WBC:
≥5.7 – ≤7.0 × 109/l and tertile 3. hs-CRP: ≥2.04 – ≤20 mg/l,
WBC: ≥7.1 – ≤15 × 109/l. The systemic inflammatory score
ranged from 2 to 6 points; 5–6 were defined as a high score. The
endpoints in the study were prostate cancer overall (Table 2), or
prostate cancer split into risk groups as separate endpoints
(Table 3). When using prostate cancer of a specific risk group as
endpoint, prostate cancer cases in other or unknown risk group
were excluded from the analysis.
Participating men with more than one measurement of hs-
CRP during follow-up (n = 2,210) were included in the data set
by using the “reshape” command in STATA, thus updating the
measured levels of inflammation-related biomarkers for the next
period at risk. We then calculated Δhs-CRP: the difference in
hs-CRP between the first and the second measurement. In sepa-
rate models, Δhs-CRP was included as a continuous variable or
dichotomized as Δhs-CRP ≥1.00 mg/l (yes/no).
Based on suggested biological mechanisms influencing our
inflammation-related biomarkers, and/or prostate cancer risk,
several variables were assessed as potential confounders. Age at
entry (continuous) and BMI (continuous), were included as
covariates in the final models. Lipid-lowering drugs (categorical),
alcohol habits (categorical), and physical activity (categorical) did
not influence our results and were not included. The analyses
with Δhs-CRP as an explanatory variable were also adjusted for
hs-CRP at baseline. We performed stratified analyses by age at
study entry (<60 years vs. ≥60 years), systolic BP (<140 mm Hg
vs. ≥140 mm Hg), BMI (<25 kg/m2 vs. ≤25 kg/m2).
The proportional hazard assumption was verified by visual
inspection of log minus log survival curves in tertiles of hs-CRP
and WBC and in groups according to Δhs-CRP or systemic
inflammation score. All statistical tests were two-sided using a
significance level of p < 0.05, and conducted with STATA/MP
version 15.1 (StataCorp LLC, College station, TX).
Data availability
The data set used in our study is available upon request, pending
permission from the Tromsø Study (www.tromsoundersokels
en.no).
Results
The cohort of 7,270 participating men had the following means:
age at entry 56.9 years, hs-CRP 2.10 mg/l, and WBC 6.62
(×109cells/l) (Table 1). A total of 509 men developed prostate
cancer during 11.8 years of follow-up. Men with one measure-
ment of inflammatory markers compared to men with two mea-
surements had a mean follow up and incidence rate of 8.4 years
and 60.9/1000 men, and 18.3 years and 124/1000 men, respec-
tively (not presented in tables). The prostate cancer cases with a
mean age at diagnosis of 71.7 years had a mean PSA at diagnosis
of 14.3 μg/l. Among prostate cancer cases, 16.1% were in the
low-risk group, 41.9% were in the intermediate-risk group,
Table 2. Hazard ratios (HR) for risk of prostate cancer by
prediagnostic hs-CRP, WBC or by a combination of hs-CRP and WBC
(systemic inflammatory score). The PROCA-life study (1994–2008)
Age-adjusted Multivariable1
Cases (n = 7,270) (n = 7,270)
Inflammatory
markers N HR (95% CI) HR (95% CI)
Hs-CRP
Continuous, mg/l 509 1.04 (1.01–1.07) 1.03 (1.00–1.07)
Continuous, 1 SD 509 1.09 (1.01–1.17) 1.09 (1.01–1.17)
Tertiles
<0.91 mg/l 131 1.00 (reference) 1.00 (reference)
0.92–2.03 mg/l 174 1.16 (0.93–1.46) 1.16 (0.92–1.46)
>2.04 mg/l 204 1.31 (1.05–1.63) 1.30 (1.04–1.63)
WBC
Continuous, x 109/l 490 1.04 (0.98–1.09) 1.04 (0.98–1.09)
Continuous, 1 SD 490 1.06 (0.97–1.17) 1.06 (0.97–1.17)
Tertiles
≤5.6 x 109/l 147 1.00 (reference) 1.00 (reference)
5.7– ≤7.0 x 109/l 196 1.46 (1.18–1.80) 1.46 (1.17–1.80)
≥7.1 x 109/l 147 1.23 (0.98–1.55) 1.23 (0.98–1.55)
Systemic inflammatory score (SIS)
Continuous
per 1 point
490 1.09 (1.02–1.17) 1.09 (1.02–1.17)
SIS low2–4 285 1.00 (reference) 1.00 (reference)
SIS high5,6 205 1.28 (1.07–1.53) 1.28 (1.06–1.53)
Δhs-CRP2
Continuous, mg/l 220 1.04 (0.99–1.09) 1.05 (1.01–1.10)
Positive change
<1.00 mg/l 155 1.00 (reference) 1.00 (reference)
≥1.00 mg/l 65 1.35 (1.01–1.80) 1.36 (1.02–1.82)
Statistically significant (p value <0.05) hazard ratios are marked in bold
letters. The systemic inflammatory score ranged from two to six points;
high systemic inflammatory score: 5–6 were defined as a high systemic
inflammatory score-score. Low systemic inflammatory score: Systemic
inflammatory score = 2, 3 and 4.
Abbreviations: BMI, body mass index; CI, confidence interval; HR, hazard
ratio; Hs-CRP, high sensitivity C-reactive protein; n, numbers; WBC, white
blood cell count.
1Adjusted for age at entry and BMI. Analyses with Δhs-CRP also adjusted
for hs-CRP at baseline.
2Δhs-CRP: Change in hs-CRP across two measurements. Analyzed in sub-
group with repeated measurements available.
Stikbakke et al. 5












24.2% in the high-risk group, and 12.1% had metastatic disease
at the time at diagnosis.
Inflammation-related biomarkers and prostate cancer risk
We observed a positive dose–response relationship between hs-
CRP and prostate cancer risk (HR per unit 1.03, 95%CI 1.00–1.07)
after adjustments for potential confounding factors (Table 2). Men
in the upper tertile of hs-CRP (>2.04 mg/l) had a 30% increased
prostate cancer risk (HR 1.30, 95% CI 1.04–1.63) compared to
men in the lower tertile of hs-CRP (<0.91 mg/l). We also observed
that an increase in hs-CRP between twomeasurements (Δhs-CRP)
of more than 1.00 mg/l increased the risk of prostate cancer by
36% (HR 1.36, 95% CI 1.02–1.82), compared to those men who
had a small increase or a decrease in hs-CRP level between two
measurements (Table 2). Time between twomeasurements did not
influence these observed results, and mean time between measure-
ments was 6.7 years (range 5.7–14.1 years) (results not presented
in table). A similar dose–response relationship was observed
between WBC and prostate cancer risk, but the results were not
statistically significant.
When the levels of hs-CRP and WBC were combined in a sys-
temic inflammatory score (range 2–6), a positive dose–response
association was observed between systemic inflammatory score
and prostate cancer risk (HR per unit 1.09, 95% CI 1.02–1.17).
Men with a high systemic inflammatory score5,6 had a 28%
increased risk of prostate cancer (HR 1.28, 95% CI 1.07–1.53)
when compared to men with a lower systemic inflammatory
score.2–4 When stratified by age at study entry (<60 years vs.
≥60 years at study entry), we observed a positive dose–response
relationship between systemic inflammation score and prostate
cancer risk (HR 1.08, 95% CI 1.00–1.17) only among men who
were ≥60 years at study entry, but interaction terms between
groups were not significant (Supporting Information Table S1).
Among those with a prediagnostic BMI ≥25 kg/m2 we observed a
1.27 times increased risk (95% CI 1.03–1.58) of prostate cancer
for men with an high systemic inflammatory score when com-
pared to men with a low score (Supporting Information Table S2).
When stratified by systolic blood pressure (<140 mm Hg
vs. ≥140 mm Hg), we observed a positive dose–response relation-
ship between hs-CRP and prostate cancer risk (HR 1.06, 95%
CI 1.02–1.11) among men who had a systolic blood pres-
sure < 140 mm Hg. Interaction terms between groups were not
significant (Supporting Information Table S3).
Inflammation-related biomarkers and severity of prostate
cancer
Men with a WBC count in the upper tertile (≥7.1 x 109cells/l),
had a 1.91 (95% CI 1.03–3.52) times increased risk of metastatic
Table 3. Age-adjusted hazard ratios (HR) for different risk groups of prostate cancer, by prediagnostic hs-CRP, WBC or by a combination of















markers Cases HR (95% CI) Cases HR (95% CI) Cases HR (95% CI) Cases HR (95% CI)
Hs-CRP
Continuous, mg/l 80 1.00 (0.92–1.09) 195 1.07 (1.03–1.22) 132 1.01 (0.95–1.08) 72 1.00 (0.92–1.09)
Continuous, 1 SD 80 1.00 (0.81–1.25) 195 1.20 (1.08–1.33) 132 1.04 (0.89–1.21) 72 1.00 (0.81–1.24)
Tertiles
<0.91 mg/l 24 1.00 (ref.) 44 1.00 (ref.) 39 1.00 (ref.) 16 1.00 (ref.)
0.92–2.03 mg/l 30 1.12 (0.66–1.92) 65 1.31 (0.90–1.93) 44 0.99 (0.64–1.53) 25 1.30 (0.69–2.43)
>2.04 mg/l 26 0.99 (0.56–1.73) 86 1.72 (1.19–2.48) 49 1.04 (0.68–1.60) 31 1.44 (0.79–2.65)
WBC
Continuous, x 109/l 77 1.01 (0.89–1.15) 192 1.03 (0.94–1.11) 126 1.00 (0.90–1.11) 66 1.11 (0.97–1.28)
Continuous, 1 SD 77 1.02 (0.80–1.29) 192 1.05 (0.90–1.21) 126 1.00 (0.83–1.21) 66 1.21 (0.95–1.55)
Tertiles
≤5.6 x 109/l 28 1.00 (ref.) 59 1.00 (ref.) 38 1.00 (ref.) 17 1.00 (ref.)
5.7– ≤7.0 x 109/l 30 1.22 (0.73–2.04) 76 1.44 (1.03–2.03) 54 1.54 (1.02–2.33) 22 1.41 (0.75–2.66)
≥7.1 x 109/l 19 0.88 (0.49–1.58) 57 1.23 (0.85–1.77) 34 1.07 (0.67–1.70) 27 1.91 (1.03–3.52)
Systemic inflammatory score
Continuous per 1 point 77 0.96 (0.80–1.14) 192 1.16 (1.04–1.30) 126 1.06 (0.88–1.17) 66 1.25 (1.02–1.51)
Low2–4 51 1.00 (ref.) 108 1.00 (ref.) 77 1.00 (ref.) 33 1.00 (ref.)
High5,6 26 0.96 (0.60–1.54) 84 1.43 (1.07–1.90) 49 1.11 (0.78–1.60) 33 1.68 (1.04–2.73)
Statistically significant (p value <0.05) hazard ratios are marked in bold letters. Values given are hazard ratios with 95% confidence interval. Numbers
may vary due to missing information. The systemic inflammatory score ranged from 2 to 6 points; High Systemic inflammatory score: 5–6 were defined
as a high systemic inflammatory score. Low systemic inflammatory score: Systemic inflammatory Score = 2, 3 and 4.
Abbreviations: CI, confidence interval; HR, hazard ratio; Hs-CRP, high sensitivity C-reactive protein; n, numbers; WBC, white blood cell count.
1Prostate cancer cases in other risk groups or unknown risk group were excluded from the analysis.
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prostate cancer when compared to men with the lowest tertile of
WBC (≤5.6 × 109/l).
We observed a dose–response association between systemic
inflammatory score and both being diagnosed within an inter-
mediate prostate cancer risk group (HR 1.16, 95% CI 1.04–1.30)
and being diagnosed with metastatic disease, (HR 1.25, 95% CI
1.02–1.51). Men with a high systemic inflammatory score5,6 had
a 43% increased risk for intermediate risk prostate cancer
(HR 1.43, 95% CI 1.07–1.90), and a 68% increased risk of meta-
static prostate cancer (HR 1.68, 95% CI 1.04–2.73) when com-
pared to men having a systemic inflammatory score between
2 and 4 (Table 3).
Discussion
In this population-based prospective study with repeated
measurements of prediagnostic inflammatory markers, we
observed that hs-CRP measured at one and two time points
was associated with prostate cancer risk in a positive dose–
response manner; among men with an increase in hs-CRP
between two measurements (≥1.00 mg/l), we observed a 36%
higher prostate cancer risk compared to those who had small
increase or a decrease in hs-CRP level. Men with a high sys-
temic inflammatory score (hs-CRP and WBC in combination)
had a 28% higher prostate cancer risk, and were more likely
to be diagnosed with metastatic prostate cancer compared to
men having a low systemic inflammatory score (2–4).
Results from previous studies of the association between hs-
CRP orWBC and prostate cancer risk have been inconsistent. Our
findings that hs-CRP measured at one time point were associated
with prostate cancer risk are supported by some studies,7,17,24 but
our results are also in contrast to others.16,18,19,21–23 In a nested
case–control study including 622 prostate cancer cases, a positive
association was observed between prediagnostic CRP and prostate
cancer risk among men with BMI <25 kg/m2, even when CRP was
measured several years before the diagnosis.21 In the present study,
we did not observe any clear pattern of variation in the associations
studied between inflammatory markers and prostate cancer when
stratified by BMI (BMI <25 kg/m2 vs. BMI ≥25 kg/m2). However,
among those with a prediagnostic BMI ≥25 kg/m2 we observed a
1.27 times increased risk (95% CI 1.03–1.58) of prostate cancer for
men with a high systemic inflammatory score when compared to
men with a low score. These findings support that excess weight
may mirror a low grade inflammation by resulting in a higher sys-
temic inflammatory score not observed among the leaner men
(BMI <25 kg/m2).
Our findings suggesting that both hs-CRP and an increase
in hs-CRP during follow-up were associated with risk of meta-
static prostate cancer are partly in line with the Swedish
AMORIS study.17 In the AMORIS study,17 CRP was dichoto-
mized into low (<10 mg/ml) and high (≥10 mg/ml) and it was
observed that CRP levels assessed on average 14 years before
being diagnosed with prostate cancer predicted worse out-
come (high-risk prostate cancer and metastatic prostate
cancer). A positive association between hs-CRP and advanced
prostate cancer is also supported by others.29–31
However, to our knowledge, this is the first study to assess
the combination of hs-CRP and WBC creating a systemic
inflammatory score in relation to both prostate cancer risk
and severity. Interestingly, our findings suggest that compared
to using either WBC or hs-CRP alone, a combination of these
markers may be more useful. The score was strongly associ-
ated with both risk for prostate cancer and for severity of
prostate cancer. Thus, an inflammatory score might be a use-
ful way of combining two or more inflammatory markers that
could be used for risk classification.24 In a large population-
based study by Morrison et al., CRP and WBC were combined
into a Z-score.32 They found an association between the inflam-
mation Z-score and risk for overall cancer, including prostate can-
cer. In contrast, in another study, a high score based on three
inflammatory biomarkers (CRP, WBC and fibrinogen) was not
associated with prostate cancer risk.33 Additionally, several studies
have questioned whether a systemic inflammatory score could be
a valuable predictive tool for worse outcome in several types of
cancers including prostate cancer,34,35 and our results support the
hypothesis that it might be valuable for prostate cancer severity.
Published studies suggest a dual effect of obesity: an increased
risk for advanced prostate cancer,36 low-grade systemic inflam-
mation,37 severity of prostate cancer and a decreased risk of local-
ized prostate cancer.38 In our study, we did not find any variation
by measured BMI (kg/m2), in contrast to others,39 but we
included only one BMI measurement. Wang et al. found that
men with an increase in BMI from normal to an overweight or
obese condition experienced increased risk of prostate cancer
compared to men with persistently normal BMI, and that this
was most pronounced for men with ISUP grade group ≥7. The
biological explanation is not fully understood, but there is evi-
dence suggesting that substantial crosstalk occurs between molec-
ular pathways involved in inflammation and obesity. Studies have
investigated the association between inflammatory markers and
hypertension,40,41 where low-grade systemic inflammation might
be a common cause. We stratified our results by systolic BP
(⋚140 mm Hg), but did not observe any significant association
between the systemic inflammatory score and risk of prostate
cancer (Supporting Information Table S3).
Inflammation is one of the hallmarks of cancer development,33
and CRP is found in blood plasma, with rising levels in response to
factors released by inflammatory associated cells as macro-
phages and fat cells.42 Chronic inflammation is evident in the
adult prostate and probably has a role in formation of lesions
such as proliferative inflammatory atrophy, which is prolifera-
tive glandular epithelium with morphological appearance of
simple atrophy that occurs in association with inflamma-
tion.2,43,44 These lesions are thought to be possible precursors
for prostate cancer.2,45 Further, there is evidence that regenerative
epithelium in response to environmental insults may precede
development of prostate intraepithelial neoplasia and early carci-
noma.44,45 The origin of prostate inflammation is multifactorial
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and in many cases without symptoms. The inflammation could be
either acute or chronic.46
The strengths of our study include its prospective and pop-
ulation-based design and the high attendance rate
(65.7–78.5%25), which lessens the chance of biased observa-
tions. In addition, a high completeness rate of identification of
prostate cancer cases (Cancer Registry of Norway) at 98.8% is
another strength.47 Furthermore, the rather long follow-up
time, broad information about baseline characteristics and
repeated measurements of hs-CRP strengthen the results
observed. All medical records for the prostate patients were
carefully reviewed by trained physicians with systematic
abstraction of histopathology and clinical characteristics. The
study was able to control for several potential confounding fac-
tors, and to address effect modification, such as age, body mass
index, smoking habits, and physical activity.
However, our study also has some limitations. The popula-
tion in Tromsø is mainly Caucasian, and the results may there-
fore not be relevant for populations including other ethnicities.
Repeated assessments of inflammation-related biomarkers were
only assessed among a subgroup of men, thus limiting the sam-
ple size. A limitation of our study is the long time between expo-
sure measurement and diagnosis. Thus, changes in various
clinical variables over time may have occurred, and two mea-
surements of variables may only in part account for the cumula-
tive effect of the markers on risk of prostate cancer. The levels of
these exposures may be affected by various factors over the life-
course and may tend to fluctuate. However, measurements of
BMI made earlier in life have been found to be strongly related
to measurements later in life.48,49 Moreover, adjustment for time
between measurement and diagnosis did not change our results.
Information regarding family history of prostate cancer was not
available and could therefore not be included in the analysis.
Conclusion
Our study supports a positive association between hs-CRP,
hs-CRP and WBC in combination and risk for both prostate
cancer and for metastatic prostate cancer. Importantly, hs-
CRP and WBC are often used in routine clinical practice, and
thus easily accessible. Our findings contribute to understand-
ing the relationship between inflammation and prostate can-
cer development, and may be useful in future research on
prostate cancer etiology and possibly prevention. However,
our results are based on a relatively small sample size and
should be interpreted with caution.
Acknowledgements
The authors would like to thank the participants of the Tromsø Study,
The Department of Community Medicine, UiT The Arctic University of
Norway; and Jeanette Engeness, Department of Clinical Pathology Univer-
sity Hospital of North Norway, Tromsø, Norway.
References
1. Hanahan D, Weinberg RA. Hallmarks of cancer:
the next generation. Cell 2011;144:646–74.
2. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflam-
mation in prostate carcinogenesis. Nat Rev Cancer
2007;7:256–69.
3. Luo JL, Tan W, Ricono JM, et al. Nuclear
cytokine-activated IKKalpha controls prostate
cancer metastasis by repressing Maspin. Nature
2007;446:690–4.
4. de Visser KE, Eichten A, Coussens LM. Paradoxi-
cal roles of the immune system during cancer
development. Nat Rev Cancer 2006;6:24–37.
5. Cooperberg MR, Broering JM, Carroll PR. Time
trends and local variation in primary treatment of
localized prostate cancer. J Clin Oncol 2010;28:
1117–23.
6. Cancer in Norway. In: Larsen IK, ed. Cancer inci-
dence, mortality, survival and prevalence in Nor-
way. Oslo: Cancer Registry of Norway, 2016.
2017.
7. Touvier M, Fezeu L, Ahluwalia N, et al. Associa-
tion between prediagnostic biomarkers of inflam-
mation and endothelial function and cancer risk:
a nested case-control study. Am J Epidemiol 2013;
177:3–13.
8. Beer TM, Lalani AS, Lee S, et al. C-reactive pro-
tein as a prognostic marker for men with
androgen-independent prostate cancer: results
from the ASCENT trial. Cancer 2008;112:
2377–83.
9. Prins RC, Rademacher BL, Mongoue-Tchokote S,
et al. C-reactive protein as an adverse prognostic
marker for men with castration-resistant prostate
cancer (CRPC): confirmatory results. Urol Oncol
2012;30:33–7.
10. Elsberger B, Lankston L, McMillan DC, et al.
Presence of tumoural C-reactive protein correlates
with progressive prostate cancer. Prostate Cancer
Prostatic Dis 2011;14:122–8.
11. Buckley DI, Fu R, Freeman M, et al. Helfand
M. C-reactive protein as a risk factor for coronary
heart disease: a systematic review and meta-
analyses for the U.S. preventive services task force.
Ann Intern Med 2009;151:483–95.
12. Ockene IS, Matthews CE, Rifai N, et al. Variability
and classification accuracy of serial high-
sensitivity C-reactive protein measurements in
healthy adults. Clin Chem 2001;47:444–50.
13. De Nunzio C, Kramer G, Marberger M, et al. The
controversial relationship between benign pros-
tatic hyperplasia and prostate cancer: the role of
inflammation. Eur Urol 2011;60:106–17.
14. Sharma S, Zapatero-Rodriguez J, O’Kennedy R.
Prostate cancer diagnostics: clinical challenges and
the ongoing need for disruptive and effective diag-
nostic tools. Biotechnol Adv 2017;35:135–49.
15. Maia MC, Hansen AR. A comprehensive review
of immunotherapies in prostate cancer. Crit Rev
Oncol Hematol 2017;113:292–303.
16. St Hill CA, Lutfiyya MN. An epidemiological
analysis of potential associations between C-
reactive protein, inflammation, and prostate
cancer in the male US population using the
2009-2010 National Health and Nutrition
Examination Survey (NHANES) data. Front
Chem 2015;3:55.
17. Arthur R, Williams R, Garmo H, et al. Serum
inflammatory markers in relation to prostate can-
cer severity and death in the Swedish AMORIS
study. Int J Cancer 2018;142:2254–62.
18. Platz EA, De Marzo AM, Erlinger TP, et al.
No association between pre-diagnostic plasma
C-reactive protein concentration and subse-
quent prostate cancer. Prostate 2004;59:
393–400.
19. Van Hemelrijck M, Jungner I, Walldius G, et al.
Risk of prostate cancer is not associated with
levels of C-reactive protein and other commonly
used markers of inflammation. Int J Cancer 2011;
129:1485–92.
20. Pierce BL, Biggs ML, DeCambre M, et al. C-
reactive protein, interleukin-6, and prostate cancer
risk in men aged 65 years and older. Cancer Cau-
ses Control 2009;20:1193–203.
21. Stark JR, Li H, Kraft P, et al. Circulating
prediagnostic interleukin-6 and C-reactive protein
and prostate cancer incidence and mortality. Int J
Cancer 2009;124:2683–9.
22. Siemes C, Visser LE, Coebergh JW, et al. C-
reactive protein levels, variation in the C-reactive
protein gene, and cancer risk: the Rotterdam
study. J Clin Oncol 2006;24:5216–22.
23. Heikkila K, Harris R, Lowe G, et al. Associations
of circulating C-reactive protein and interleukin-6
with cancer risk: findings from two prospective
cohorts and a meta-analysis. Cancer Causes Con-
trol 2009;20:15–26.
24. Toriola AT, Laukkanen JA, Kurl S, et al.
Prediagnostic circulating markers of inflammation
8 Inflammatory serum markers












and risk of prostate cancer. Int J Cancer 2013;133:
2961–7.
25. Eggen AE, Mathiesen EB, Wilsgaard T, et al. The
sixth survey of the Tromso Study (Tromso 6) in
2007-08: collaborative research in the interface
between clinical medicine and epidemiology:
study objectives, design, data collection proce-
dures, and attendance in a multipurpose
population-based health survey. Scand J Public
Health 2013;41:65–80.
26. Jacobsen BK, Eggen AE, Mathiesen EB, et al.
Cohort profile: the Tromso Study. Int J Epidemiol
2012;41:961–7.
27. Epstein JI, Allsbrook WC Jr, Amin MB, et al. The
2005 International Society of Urological Pathology
(ISUP) consensus conference on Gleason grading
of prostatic carcinoma. Am J Surg Pathol 2005;29:
1228–42.
28. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU
guidelines on prostate cancer. Part 1: screening,
diagnosis, and local treatment with curative
intent-update 2013. Eur Urol 2014;65:124–37.
29. Aldemir M, Ener K, Dehni D, et al. KayÄgil Ã.
evaluation of the relationship between prostate
cancer and serum inflammation markers.
Nephrourol Mon 2010;02:244–50.
30. Lehrer S, Diamond EJ, Mamkine B, et al. C-
reactive protein is significantly associated with
prostate-specific antigen and metastatic disease in
prostate cancer. BJU Int 2005;95:961–2.
31. Chang C-C, Lin ATL, Chen K-K, et al. The signif-
icance of plasma C-reactive protein in patients
with elevated serum prostate-specific antigen
levels. Urolog Sci 2010;21:88–92.
32. Morrison L, Laukkanen JA, Ronkainen K, et al.
Inflammatory biomarker score and cancer:
a population-based prospective cohort study.
BMC Cancer 2016;16:80.
33. Allin KH, Bojesen SE, Nordestgaard BG. Inflam-
matory biomarkers and risk of cancer in 84,000
individuals from the general population. Int J
Cancer 2016;139:1493–500.
34. Shibutani M, Maeda K, Nagahara H, et al. The
prognostic value of the systemic inflammatory
score in patients with unresectable metastatic
colorectal cancer. Oncol Lett 2018;16:666–72.
35. McMillan DC. The systemic inflammation-based
Glasgow prognostic score: a decade of experience
in patients with cancer. Cancer Treat Rev 2013;39:
534–40.
36. Giovannucci EL, Liu Y, Leitzmann MF, et al. A
prospective study of physical activity and incident
and fatal prostate cancer. Arch Intern Med 2005;
165:1005–10.
37. Choi J, Joseph L, Pilote L. Obesity and C-reactive
protein in various populations: a systematic
review and meta-analysis. Obes Rev 2013;14:
232–44.
38. Discacciati A, Orsini N, Wolk A. Body mass index
and incidence of localized and advanced prostate
cancer–a dose-response meta-analysis of prospec-
tive studies. Ann Oncol 2012;23:1665–71.
39. Wang K, Chen X, Gerke TA, et al. BMI trajecto-
ries and risk of overall and grade-specific prostate
cancer: an observational cohort study among men
seen for prostatic conditions. Cancer Med 2018;7:
5272–80.
40. Dauphinot V, Roche F, Kossovsky MP, et al. C-
reactive protein implications in new-onset hyper-
tension in a healthy population initially aged
65 years: the proof study. J Hypertens 2009;
27:736–43.
41. Fukutomi M, Hoshide S, Eguchi K, et al. Low-
grade inflammation and ambulatory blood pres-
sure response to antihypertensive treatment: the
ALPHABET study. Am J Hypertens 2013;26:
784–92.
42. Thompson D, Pepys MB, Wood SP. The physio-
logical structure of human C-reactive protein and
its complex with phosphocholine. Structure 1999;
7:169–77.
43. Nakai Y, Nonomura N. Inflammation and pros-
tate carcinogenesis. Int J Urol 2013;20:150–60.
44. Davidsson S, Fiorentino M, Andren O, et al.
Inflammation, focal atrophic lesions, and prostatic
intraepithelial neoplasia with respect to risk of
lethal prostate cancer. Cancer Epidemiol Bio-
markers Prev 2011;20:2280–7.
45. Bostwick DG, de la Roza G, Dundore P, et al.
Intraepithelial and stromal lymphocytes in the
normal human prostate. Prostate 2003;
55:187–93.
46. Moreira DM, Nickel JC, Gerber L, et al. Baseline
prostate inflammation is associated with a reduced
risk of prostate cancer in men undergoing repeat
prostate biopsy: results from the REDUCE study.
Cancer 2014;120:190–6.
47. Larsen IK. Data quality at the Cancer Registry of
Norway. Eur J Cancer 2009;45:1218–31.
48. Evensen E, Wilsgaard T, Furberg AS, et al. Track-
ing of overweight and obesity from early child-
hood to adolescence in a population-based cohort
- the Tromso Study, fit futures. BMC Pediatr
2016;16:64.
49. Wilsgaard T, Jacobsen BK, Schirmer H, et al.
Tracking of cardiovascular risk factors: the
Tromso study, 1979-1995. Am J Epidemiol 2001;
154:418–26.
Stikbakke et al. 9
Int. J. Cancer: 00, 00–00 (2019) © 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC
C
an
ce
r
E
pi
de
m
io
lo
gy
